NCT06364696View on ClinicalTrials.gov

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Solid Tumor
Interventions
DRUG

ASP4396

Intravenous (IV) infusion

Trial Locations (7)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

14627

RECRUITING

University of Rochester, Rochester

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

49546

RECRUITING

START Midwest, Grand Rapids

66205

RECRUITING

University of Kansas Cancer Center, Westwood

75039

RECRUITING

NEXT Oncology Dallas, Irving

84119

RECRUITING

START Mountain Region, West Valley City

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT06364696 - A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | Biotech Hunter | Biotech Hunter